Filtered By:
Source: BioFactors
Condition: Metabolic Syndrome
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
AbstractApolipoprotein CIII (apoCIII) is increased in obesity-induced insulin resistance and type-2 diabetes. Emerging evidences support the advantages of small interfering RNAs (siRNAs) to target disease-causing genes. The aim of this study was to develop siRNAs for in vivo silencing of apoCIII and investigate if this results in metabolic improvements comparable to what we have seen using antisense oligonucelotides against apoCIII. Twenty-four siRNAs were synthesized and tested in a dual luciferase reporter assay. The eight best were selected, based on knockdown at 20 nM, and of these, two were selected based on IC50 v...
Source: BioFactors - September 1, 2022 Category: Biochemistry Authors: Patricia Recio ‐López,
Ismael Valladolid‐Acebes,
Philipp Hadwiger,
Markus Hossbach,
Monika Krampert,
Carla Prata,
Per‐Olof Berggren,
Lisa Juntti‐Berggren Tags: RESEARCH COMMUNICATION Source Type: research
